About Guardant
Guardant Health is a leading precision oncology company transforming cancer care through innovative blood-based testing solutions. The company has performed over 1,000,000 blood tests used by 12,000 doctors to inform treatment decisions and improve clinical outcomes across all stages of cancer. Their comprehensive portfolio includes Shield, a blood test for colorectal cancer screening that offers a more convenient alternative to colonoscopy and stool-based testing; Guardant360 Liquid CDx, the #1 FDA-approved liquid biopsy with the largest genomic and epigenomic panel featuring genome-wide methylation coverage; Guardant360 Tissue, an advanced tissue test integrating DNA, RNA, and epigenomics; and Guardant Reveal for minimal residual disease detection and therapy response monitoring. The company's InfinityAI platform leverages purpose-built artificial intelligence and machine learning to unlock clinically meaningful insights from complex, multimodal, longitudinal data. Guardant Health serves healthcare providers, health systems, institutional partners, and biopharma companies, delivering precision oncology solutions that enable earlier cancer detection, personalized treatment selection, and improved patient outcomes. The company is committed to conquering cancer through the power of blood tests and data-driven insights.
Mission & Story
Mission
Conquering cancer through data
Founding Story
Co-founded by Helmy Eltoukhy (Co-CEO), who states 'Our focus is always on what will have the greatest impact on patients.'
Clinical Focus
Medical conditions and clinical areas addressed by Guardant.
Who It Serves
Milestones & Awards
Recent Milestones
FDA approval of Guardant360 Liquid CDx with 100x expanded footprint (May 2026). American Cancer Society recommendation of Shield blood test in colorectal cancer screening guidelines (May 2026). FDA approval of Guardant360 CDx as companion diagnostic for Boehringer Ingelheim's HERNEXEOS (June 2026).
Awards & Recognition
#1 liquid biopsy based on brand utilization market research
Key Partnerships
Social & Media
Latest Updates
Bringing Colorectal Cancer Screening Awareness to the Faith-Based Community
Guardant wins FDA approval for updated liquid biopsy
Blood testing is now included in screening recommendations for colon and rectal cancer
Patrick Dempsey raises awareness for men’s health
Reflecting on Colorectal Cancer Awareness Month
Company Details
- Headquarters
- Palo Alto, CA, USA
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingSecurity & Compliance
Official Sources
Similar Companies in this Market
View all 60 →
23andMe
23andMe uses AI to analyze genetic data and provide personalized health summaries, risk assessments, and wellness recommendations based on genomic insights.
2bPrecise
AI-powered precision medicine platform for personalized treatment recommendations and genomic analysis.
ACT Genomics
AI-powered genomic analysis platform for precision medicine and personalized treatment recommendations.
Adaptive Biotechnologies
Adaptive Biotechnologies uses AI and machine learning to decode the immune system and identify disease-specific immune signatures for diagnosis and personalized treatment.
Ambry Genetics
Ambry Genetics is a leading clinical genetic testing laboratory specializing in hereditary cancer, rare disease, cardiology, and neurology testing. The company provides advanced genetic testing solutions with paired DNA/RNA analysis and comprehensive patient support programs.
Ataraxis
Ataraxis develops AI-native precision medicine tools that predict patient outcomes and treatment response in oncology. Their flagship product, Ataraxis Breast, provides clinically validated prognostic and predictive tests for breast cancer using multi-modal AI analysis of pathology images and clinical data.
Avenda Health
Avenda Health develops Unfold AI, an FDA-cleared artificial intelligence platform that creates 3D cancer estimation maps for prostate cancer. The technology analyzes standard-of-care data (MRI, biopsy, pathology, PSA) to visualize cancer location and extent, helping physicians make more informed treatment decisions and improve patient outcomes.
Base Genomics
Base Genomics appears to be a company in the Precision Medicine & Genomics space, but the scraped website content is empty or inaccessible, preventing detailed analysis of their offerings and target market.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.